Preparation of IL-CDs and their application in drugs for inhibiting biofilm growth and promoting wound healing

Through the preparation of IL-CDs, high-temperature hydrothermal synthesis of Vinyl-ILs and GTA is used to form IL-CDs that retain alkyl chains and positively charged imidazole groups, solving the treatment problems of antibiotic resistance and bacterial biofilms, significantly improving the Its bactericidal and biofilm inhibitory ability to promote wound healing.

CN118078857BActive Publication Date: 2024-12-06LANZHOU INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410234158.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-01
Publication Date
2024-12-06
Estimated Expiration
2044-03-01

AI Technical Summary

Technical Problem

The rapid spread of antibiotic resistance has led to bacterial infections becoming a threat to human health again. Traditional antibiotics are difficult to effectively treat bacterial biofilm and wound infections, and bacterial infection delays wound healing.

Method used

Using the preparation method of IL-CDs, the high-temperature hydrothermal synthesis of Vinyl-ILs and GTA is formed to retain alkyl chains and positively charged imidazole groups, using their enhanced antibacterial activity to fight Staphylococcus aureus and inhibit biofilm Form and promote healing in the wound.

Benefits of technology

IL-CDs significantly improved the bactericidal efficiency and biofilm inhibition rate of Staphylococcus aureus, had good hematocompatibility and low cytotoxicity, and could effectively promote wound healing and significantly improved the wound healing rate of the treatment group.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118078857B_ABST
    Figure CN118078857B_ABST
Patent Text Reader

Abstract

The present invention provides a method for preparing ionic liquid-derived carbon dots (IL‑CDs) and their use in drugs for inhibiting biofilm growth and promoting wound healing. Based on the reaction of vinyl and epoxy groups in two precursors, vinyl imidazolium ionic liquid and 2,3‑epoxypropyltrimethylammonium chloride, the present invention synthesizes IL‑CDs with enhanced antibacterial activity by a one-pot hydrothermal method. IL‑CDs retain the key antibacterial structures of vinyl imidazolium ionic liquids: alkyl chains and positively charged imidazole groups, and have better antibacterial effects on Staphylococcus aureus than commercially available antibacterial agents (Jieyoushen). At the same time, IL‑CDs have good biocompatibility, can effectively inhibit bacterial biofilm growth and promote the healing of bacterially infected wounds. The IL‑CDs provided by the present invention can be used as a potential candidate drug for the treatment of diseases caused by Staphylococcus aureus infections, providing a new idea for the antibacterial application of ionic liquid-derived materials.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a preparation method and application of IL-CDs, mainly to applications in antibacterial, anti-biofilm and wound healing promotion, and belongs to the field of nanomaterials and nanomedicine. Background Art

[0002] The emergence and rapid spread of antibiotic resistance has led to diseases caused by bacterial infections being once again recognized as a serious threat to human health. Bacterial biofilms are the main form of bacterial infection. Studies have shown that 80% of bacterial infection-related diseases are caused by biofilms, such as infections of implantable devices-medical catheters. The formation of biofilms may lead to the accumulation of antibiotic resistance genes, making it more likely to induce antibiotic resistance. In addition, bacterial infections can delay the healing process of open wounds, cause complications such as sepsis and multiple organ failure, and even lead to death in severe cases. Therefore, it is urgent to develop new antibacterial agents for the treatment of bacterial infections to alleviate or reverse the crisis brought about by bacterial resistance.

[0003] The rapid development of nanoscience and technology has provided promising alternatives for antimicrobial therapy. Compared with traditional antibiotics (derived from microorganisms or natural products), nanomaterials have many unique physical and chemical properties, which can circumvent existing acquired resistance mechanisms and are not easy to induce bacterial resistance. Carbon dots (CDs), a new type of carbon-based nanomaterial, have the characteristics of good water solubility, small nanoscale (easier to enter cells to exert their effects), easy surface modification, abundant raw material sources (the properties of CDs can be regulated by selecting appropriate precursors), excellent fluorescence properties and good biocompatibility. They are widely used in bioimaging, drug delivery, anticancer therapy and antibacterial therapy.

[0004] CDs synthesized with antibacterial molecules as precursors usually retain the antibacterial active groups of the precursors and have better antibacterial properties than the raw materials, which may be due to the positive charge or the strengthening of the antibacterial active groups. Antibacterial molecules composed of organic cations and inorganic or organic anions, ionic liquids (ILs), can exert antibacterial activity through electrostatic effects and hydrophobic effects of alkyl chains. The structure of ILs can significantly affect its antibacterial activity, such as the type of anions and cations, the length of the alkyl chain, and the polymer effect. Therefore, ILs with excellent antibacterial activity can be customized by selecting the synthetic unit structure, which makes ILs increasingly influential in the development of non-antibiotic treatments. At present, there are few antibacterial applications of IL-CDs (ionic liquid-derived carbon dots), and the main application areas are sensing, catalysis, and bioimaging. Summary of the invention

[0005] In view of the problems existing in the above background technology, the present invention provides a method for preparing IL-CDs with antibacterial activity, and the application of the IL-CDs in antibacterial, anti-biofilm and wound healing.

[0006] 1. Preparation of IL-CDs

[0007] (1) Preparation of vinyl imidazolium ionic liquid (Vinyl-ILs): 1-vinylimidazole and bromoalkane are mixed in a molar ratio of 1:1, stirred and reacted at room temperature for 48 to 96 hours, and the obtained product is washed with ether and ethyl acetate for 3 to 5 times, and then dried in a vacuum oven at 50°C for 48 hours. The bromoalkane is one of bromooctane, bromododecane, and bromohexadecane.

[0008] (2) Preparation of IL-CDs: First, 1 mL of 2,3-epoxypropyltrimethylammonium chloride (GTA) aqueous solution was stirred at 140-180°C for 10-25 min, and then 1 mL of Vinyl-ILs aqueous solution was added and stirred at 140-180°C for 30-45 min. After cooling to room temperature, the mixture was diluted with deionized water, filtered through a filter membrane, dialyzed, and freeze-dried to obtain IL-CDs. The Vinyl-ILs is one of 1-octyl-3-vinylimidazolium bromide (Vinyl-C8), 1-dodecyl-3-vinylimidazolium bromide (Vinyl-C12), and 1-hexadecyl-3-vinylimidazolium bromide (Vinyl-C16); the molar ratio of GTA to Vinyl-ILs is 1:0.5-1:2; the concentration of the GTA and Vinyl-ILs aqueous solution is 0.5-0.8 mM / mL; and the membrane filtration and dialysis process is: after filtering with a 0.22 µm filter membrane, dialyzing in a dialysis bag with a molecular weight cutoff of 500-1000 for 24-72 hours.

[0009] Synthesis mechanism of the present invention: In order to retain the antibacterial structure of ILs—alkyl chains and positively charged imidazole groups, in order to obtain IL-CDs with enhanced antibacterial activity, we selected Vinyl-ILs and GTA as two precursors for synthesizing IL-CDs. During the high-temperature hydrothermal synthesis process, Vinyl-ILs and GTA are polymerized through the ring-opening reaction of vinyl and epoxy groups, and further carbonized to form IL-CDs that retain antibacterial functional groups (alkyl chains and positively charged imidazole groups).

[0010] 2. Structural Characterization of Vinyl-ILs and IL-CDs

[0011] Take Vinyl-C8 and IL-C8-CD prepared in Example 1 of the present invention as examples.

[0012] Figure 1This is the H NMR spectrum of Vinyl-C8 obtained in the present invention. Figure 1 The successful preparation of Vinyl-C8 can be demonstrated.

[0013] Figure 2 Transmission electron microscopy (A), particle size distribution (B) and XRD (C) images of IL-C8-CD prepared in the present invention. It can be seen that IL-C8-CD is quasi-spherical and has good dispersion; it is small in size and evenly distributed, with an average size of about 2.25 nm. In the high-resolution transmission electron microscopy (HRTEM) image, the (100) crystal plane of graphite matches the CD crystal stripes with a spacing of 0.21 nm. The (002) crystal plane corresponds to the peak at 23° in the XRD pattern. The (100) crystal plane corresponds to the peak at 42°, which is consistent with the measurement results in HRTEM.

[0014] Figure 3 The infrared spectrum (FT-IR) of IL-C8-CD obtained in the present invention is shown in the FT-IR spectrum. It can be seen from the FT-IR spectrum that IL-C8-CD does not retain the 3070 cm-1 of Vinyl-C8. -1 The CH stretching vibration peak of olefins is at 2927 cm -1 and 2857 cm -1 The CH stretching vibration peaks of methyl and methylene at 1650 cm -1 and 1160 cm -1 The peaks related to the imidazole group were retained. In addition, the peak at 1265 cm-1 did not appear in the FT-IR spectrum of IL-C8-CD. -1 The CH stretching vibration peak of the epoxy group is at 1718 cm -1 The stretching vibration peak of C=O appeared at , which indicated that the epoxy group of GTA opened to form C=O. This proved that IL-C8-CD retained the alkyl chain of Vinyl-C8 and the positively charged imidazole group through the ring-opening reaction of vinyl and epoxy groups.

[0015] Figure 4 The XPS full spectrum (A) and fine spectrum (BD) of IL-C8-CD obtained by the present invention. The XPS full spectrum shows that the material is composed of three elements: C, N, and O. The high-resolution C1s spectrum shows two peaks at 284.7 and 285.9 eV, which are attributed to CC / C=C bonds and CN / CO bonds, respectively. Two signal peaks at 399.1 and 401.7 eV were obtained from the high-resolution N1s spectrum analysis, corresponding to CNC and C-N+ structures, respectively. The high-resolution O1s spectrum analyzed two peaks at 531.9 and 532.4 eV, which are attributed to O=C-OH and O=CN, respectively. The XPS and FT-IR results are consistent, both indicating that IL-C8-CD retains the antibacterial structure of Vinyl-C8: alkyl chain and imidazole group.

[0016] 3. Antibacterial properties of IL-CDs

[0017] 1. Enhanced antibacterial activity of IL-CDs

[0018] Dilute the Staphylococcus aureus suspension to 10 6 ~10 7 CFU / mL. The bacterial suspension of the above concentration was mixed with an equal volume of IL-C8-CD, GTA or Vinyl-C8 solution of the same concentration (20 μg / mL) and incubated at 37 °C, 180 rpm in a shaker for 2 h. After the incubation, 100 μL of the 1000-fold diluted mixture was spread on LB solid culture medium, and incubated upside down in a constant temperature and humidity incubator at 37 °C for 20-24 h, and then the colony growth was recorded and the colony count was performed. Analysis Figure 5 It can be seen that IL-C8-CD has enhanced antibacterial activity, and its bactericidal efficiency against Staphylococcus aureus is significantly higher than that of GTA and Vinyl-C8.

[0019] 2. Comparison of antibacterial effect with Jieyoushen antibacterial agent

[0020] Different concentration gradients of IL-C8-CD and Jieyoushen antibacterial agent were combined with Staphylococcus aureus suspension (10 6 ~10 7 CFU / mL) for 2 h, take 100 μL of the 1000-fold diluted mixture and apply it on LB solid medium, incubate it upside down in a 37°C constant temperature and humidity incubator for 20-24 h, take photos to record the growth of colonies and count the colonies. Figure 6 It can be seen that the bactericidal effect of IL-C8-CD on Staphylococcus aureus is significantly better than that of Jieyoushen antibacterial agent. At a concentration of 5 μg / mL, the bactericidal efficiency of IL-C8-CD reached 100%, while the bactericidal efficiency of Jieyoushen antibacterial agent was only 21%.

[0021] 4. Anti-biofilm performance of IL-CDs

[0022] The ability of IL-C8-CD to inhibit biofilm formation of Staphylococcus aureus was evaluated by the crystal violet quantitative method. Staphylococcus aureus was cultured in LB medium, mixed with different concentrations of IL-C8-CD solution and added to a 96-well plate (the final concentration of the bacterial solution was 10 6CFU / mL, the final concentration of IL-C8-CD was 0, 200, 250, 300, 350, 400 μg / mL). The 96-well plate was incubated in a 37 °C incubator for 48 h and gently washed three times with PBS to remove planktonic bacteria. The biofilm formed at the bottom of the well was fixed with ethanol for 20 min. Then it was stained with 0.1% crystal violet for 15 min and washed several times with PBS to remove excess dye. Finally, an equal volume of 30% acetic acid was added to each well to dissolve it, and the OD590 was measured to calculate the biofilm inhibition rate. Figure 7 As shown in the figure, the inhibition rate of IL-C8-CD on S. aureus biofilm increased with the increase of concentration. The inhibition rate of IL-C8-CD at 400 μg / mL on S. aureus biofilm reached 90.72%, while below 200 μg / mL, IL-C8-CD had no obvious inhibitory effect on the growth of S. aureus biofilm.

[0023] 5. Biocompatibility of IL-CDs

[0024] 1. Blood compatibility

[0025] 100 μL of red blood cell suspension (2 vol%) was placed in a 96-well plate and mixed with 100 μL of IL-CDs saline solution of different concentrations to achieve the required concentration of the experiment (the final concentration of IL-C8-CD was 0, 2.5, 5, 10, 20, 40, 60, 80 and 100 μg / mL). Pure water was used as the positive control (Positive) and saline as the negative control (Negative). After incubation at 37 °C for 3 h, centrifugation was performed at 1200 rpm for 15 min. The absorbance of the supernatant was measured at 540 nm, and the hemolysis rate was calculated. At a concentration of 100 µg / mL, the hemolysis rate of IL-C8-CD was less than 5%, indicating that IL-C8-CD has good blood compatibility (see Figure 8 A).

[0026] 2. Cytotoxicity

[0027] The activity of the cells was determined by using the standard methylthiazolyl tetrazolium assay (MTT). Cervical cancer cells (HeLa, A549) at a density of 5000 cells / well were incubated in a 96-well plate for 24 h. Then, different concentrations of IL-CDs were added to each cell culture medium. After 24 h of incubation, MTT solution was added to each well and incubated for another 4 h. Subsequently, the culture medium was removed and DMSO (100 μL) was added to the wells. The well plate was gently shaken to dissolve the precipitate formed, and the absorbance was measured using a Bio-Rad model-680 microplate reader. Figure 8As shown in (B), after HeLa cells were co-cultured with 100 µg / mL IL-C8-CD for 24 h, the cell viability was still over 90%, indicating that the in vitro cytotoxicity of IL-C8-CD was negligible.

[0028] 6. Application of IL-CDs in wound healing

[0029] After the mice were anesthetized by intraperitoneal injection of 10% chloral hydrate solution, a circular wound with a diameter of about 10 mm was cut with surgical scissors. Subsequently, 100 μL of Staphylococcus aureus bacterial suspension (3.0×10 8 CFU / mL) and fixed the infection with medical sterile gauze and tape for 24 h. 100 μL IL-C8-CD solution (100μg / mL) and 100μL PBS solution were dripped onto the wounds of the treatment group and the control group, respectively, and treated every 24 h. The wounds were photographed and the weight changes of the mice were recorded on the 0th, 1st, 2nd, 4th, 6th, 8th, 10th, and 12th days of treatment, and the wound area was analyzed using ImageJ software. The mice were killed on the 12th day, and the wound tissues of the two groups of mice were collected and fixed with paraformaldehyde solution (4%) for pathological analysis by H&E staining.

[0030] like Fig. 9 As shown in A and 9B, IL-C8-CD can significantly accelerate wound healing, and the wound healing rate of the control group was significantly lower than that of the treatment group. At 8 days of treatment, the difference in wound healing rates between the two groups was the largest, with the wound healing rate of the IL-C8-CD treatment group reaching 84.07%, while the wound healing rate of the control group was only 37.31%. After 12 days of treatment, the wounds in the IL-C8-CD treatment group were completely repaired and hair began to grow again, while the wounds in the control group had not yet healed. H&E staining results of wound tissues of IL-C8-CD and control groups after 12 days of treatment ( Fig. 9 C) shows that thickened capillaries and red blood cell aggregation were found in the wound tissue of the control group, indicating that edema and inflammatory cells infiltrated the wound tissue (dark blue area); while there was no red blood cell aggregation and inflammatory cell distribution in the wound tissue of the treatment group, and fibroblasts migrated and proliferated significantly. The above results show that IL-C8-CD can effectively fight bacterial infection and promote wound healing.

[0031] In summary, the IL-CDs provided by the present invention can be used as potential candidate drugs for treating diseases caused by Staphylococcus aureus infections, and provide a new idea for the antibacterial application of ionic liquid (ILs) derived materials. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is the H NMR spectrum of Vinyl-C8 in Example 1 of the present invention.

[0033] Figure 2 TEM (A), particle size distribution (B) and XRD (C) images of IL-C8-CD in Example 1 of the present invention.

[0034] Figure 3 This is the infrared spectrum (FT-IR) of IL-C8-CD in Example 1 of the present invention.

[0035] Figure 4 The XPS full spectrum (A) and fine spectrum (BD) of IL-C8-CD in Example 1 of the present invention.

[0036] Figure 5 The plate photograph (A) and bacterial survival rate (B) of Staphylococcus aureus under the action of IL-C8-CD, GTA and Vinyl-C8 at the same concentration in Example 1 of the present invention are shown.

[0037] Figure 6 The figures are the plate photographs (A) and the bacterial survival rates (B) of Staphylococcus aureus under the action of different concentrations of IL-C8-CD and Jieyoushen antibacterial agent in Example 1 of the present invention.

[0038] Figure 7 The crystal violet staining image (A) and the biofilm inhibition rate (B) of Staphylococcus aureus biofilm under the action of different concentrations of IL-C8-CD in Example 1 of the present invention are shown.

[0039] Figure 8 Graph (A) shows the hemolysis rate of mouse erythrocytes and graph (B) shows the survival rate of HeLa cells under the action of different concentrations of IL-C8-CD in Example 1 of the present invention.

[0040] Fig. 9 The wound pictures (A) and wound healing rate (B) of the IL-C8-CD and control groups at different treatment time points in Example 1 of the present invention, and the H&E staining (C) of the wound tissues of the IL-C8-CD and control groups after 12 days of treatment. DETAILED DESCRIPTION

[0041] The preparation method of IL-CDs in the present invention is further described below through specific examples.

[0042] Example 1

[0043] (1) Preparation of Vinyl-C8: 1-vinyl imidazole and octyl bromide were mixed in a molar ratio of 1:1 and stirred at room temperature for 72 h. The obtained product was washed with ether and ethyl acetate three times and then dried in a vacuum oven at 50 °C for 48 h to obtain Vinyl-C8.

[0044] (2) Preparation of IL-C8-CD: First, 1 mL of GTA aqueous solution (0.0985 g / mL, 0.65 M) was stirred at 170°C for 15 min, and then 1 mL of Vinyl-C8 aqueous solution (0.1867 g / mL, 0.65 M) was added and stirred at 170°C for 35 min. After cooling to room temperature, 3 ml of deionized water was added to ultrasonically dissolve the viscous material. Then, a dark brown liquid was obtained by filtration with a 0.22 µm filter membrane. The above liquid was dialyzed in a dialysis bag with a molecular weight cutoff of 1000 for 48 h and freeze-dried to obtain a solid powder.

[0045] Example 2

[0046] (1) Preparation of Vinyl-C12: 1-vinylimidazole and dodecane bromide were mixed in a molar ratio of 1:1 and stirred at room temperature for 72 h. The resulting product was washed with ether and ethyl acetate three times and then dried in a vacuum oven at 50 °C for 48 h to obtain Vinyl-C12.

[0047] (2) Preparation of IL-C12-CD: First, 1 mL of GTA aqueous solution (0.0985 g / mL, 0.65 M) was stirred at 170°C for 15 min, and then 1 mL of Vinyl-C12 aqueous solution (0.2231 g / mL, 0.65 M) was added and stirred at 170°C for 35 min. After cooling to room temperature, 3 ml of deionized water was added to ultrasonically dissolve the viscous material. Then, a dark brown liquid was obtained by filtration with a 0.22 µm filter membrane. The above liquid was dialyzed in a dialysis bag with a molecular weight cutoff of 1000 for 48 h and freeze-dried to obtain a solid powder.

[0048] Example 3

[0049] (1) Preparation of Vinyl-C16: 1-vinylimidazole and hexadecane bromide were mixed in a molar ratio of 1:1 and stirred at room temperature for 72 h. The resulting product was washed with ether and ethyl acetate three times and then dried in a vacuum oven at 50°C for 48 h to obtain Vinyl-C16.

[0050] (2) Preparation of IL-C16-CD: First, 1 mL of GTA aqueous solution (0.0985 g / mL, 0.65 M) was stirred at 170°C for 15 min, and then 1 mL of Vinyl-C16 aqueous solution (0.2595 g / mL, 0.65 M) was added and stirred at 170°C for 35 min. After cooling to room temperature, 3 ml of deionized water was added to ultrasonically dissolve the viscous material. Then, a dark brown liquid was obtained by filtration with a 0.22 µm filter membrane. The above liquid was dialyzed in a dialysis bag with a molecular weight cutoff of 1000 for 48 h and freeze-dried to obtain a solid powder.

Claims

1. A method for preparing IL-CDs, characterized in that: The following steps are involved: (1) Preparation of vinyl imidazolium ionic liquid: 1-vinylimidazole and bromoalkane were mixed at a molar ratio of 1:

1. The mixture was stirred at room temperature for 48-96 h; the obtained product was washed with ether and ethyl acetate for 3-5 times. Then dry in a vacuum oven at 50°C for 48-60h; the brominated alkane is octyl bromide, dodecyl bromide, decanyl bromide One of the hexanes; (2) Preparation of IL-CDs: First, take 1 mL of 2,3-epoxypropyltrimethylammonium chloride aqueous solution and Stir the reaction at 140-180°C for 10-25 min, then add 1 mL of the vinyl imidazolium ion described in step (1) The liquid aqueous solution was stirred and reacted at 140-180°C for 30-45 min. After cooling to room temperature, the The precipitate was diluted with water, filtered through a filter membrane, dialyzed and freeze-dried to obtain IL-CDs.

2. The method for preparing IL-CDs according to claim 1, characterized in that: In step (1), The vinyl imidazolium ionic liquid is 1-octyl-3-vinylimidazolium bromide, 1-dodecyl-3-vinyl One of imidazolium bromide or 1-hexadecyl-3-vinylimidazolium bromide.

3. The method for preparing IL-CDs according to claim 1, characterized in that: In step (2), The molar ratio of the 2,3-epoxypropyltrimethylammonium chloride to the vinyl imidazolium ionic liquid is 1:0.5 to 1:

2.

4. The method for preparing IL-CDs according to claim 1, characterized in that: In step (2), The concentration of the 2,3-epoxypropyltrimethylammonium chloride and vinyl imidazolium ionic liquid aqueous solution is 0.5 to 0.8 M。 5. The method for preparing IL-CDs according to claim 1, characterized in that: In step (2), After filtering with a 0.22 µm filter membrane, dialyze in a dialysis bag with a molecular weight cut-off of 500-1000 24~72 h。 6. The IL-CDs obtained by the preparation method according to any one of claims 1 to 5 are used in the preparation of antibacterial and wound-promoting Application of oral healing drugs.